COVID-19

Rural areas lag well behind their urban counterparts when it comes to COVID-19 vaccinations

Molnupiravir is an oral antiviral for the treatment of mild to moderate COVID-19 in adults at high risk of severe disease.

COVID-19 updates and news to know as of February 28, 2022.

A large cohort study offers important data on what factors are frequently tied to severe cases of COVID-19 in the pediatric population.

The days of blanket mitigation strategies to protect children from COVID-19 are becoming a thing of the past. One model sheds light onto determining when strategies can be relaxed.

Recent treatment may affect the antibody response, particularly among those with hematologic cancers.

COVID-19 updates and news to know as of February 21, 2022.

Does anxiety justify an exemption from vaccine mandates among health care workers?

Patients with chronic lymphocytic leukemia experienced functional T cell and antibody responses after receiving a vaccine for COVID-19.

NVX-CoV2373 was evaluated in adolescents aged 12 to 17 years.

The FDA meeting to discuss extending the Pfizer/BioNTech EUA to children aged 6 months to 4 years has been postponed until data on a third dose has been studied.

The safety of the Pfizer/BioNTech COVID-19 vaccine in pregnant women, for both mother and baby, has been dependent on observation during the rollout. A large population trial provides further support for the vaccine’s safety.

As respiratory viruses and COVID-19 variants lurk seemingly everywhere, here’s how best to detect and differentiate.

A third dose of an mRNA COVID-19 vaccine was safe and associated with modestly increased levels of antibodies in patients with reduced protective humoral immunity before reimmunization.

COVID-19 updates and news to know as of February 7, 2022.

Pfizer received an emergency use authorization (EUA) for Paxlovid, an oral pill for the treatment of mild to moderate COVID-19 in certain adult and pediatric populations.

Several institutions have published guidance on how to treat patients hospitalized with COVID-19.

Spikevax is now the second COVID-19 vaccine approved by regulators.

NVX-CoV2373 is a protein-based COVID-19 vaccine for adults 18 years and older.

COVID-19 updates and news to know as of January 31, 2022.

Further research is needed to determine causation.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.

First time outpatient visits for mental health services were sharply increased compared with the period before the pandemic.

The COVID-19 vaccine protects against disease and severe effects, but can it help reduce the risk of multisystem inflammatory syndrome in children (MIS-C)?

Some evidence suggests that people with HIV may be more likely to develop a severe case of COVID-19 and antiretroviral therapy may provide some protection against infection.

CMS and state officials are using payment incentives, data collection and program requirements to start edging the lofty ideals of health equity toward reality.

The monoclonal antibody was conditionally recommended for the treatment of mild to moderate COVID-19 in patients at high risk of hospitalization.

With increased infectivity of Omicron, the CDC has updated the guidance on the best mask types to use.

Spending may have reached $130 million despite a lack of evidence that ivermectin effectively treats COVID-19.

COVID-19 updates and news to know as of January 17, 2022.